Omalizumab patients reported the greatest improvement for reducing waking with symptoms in the morning (Symptoms domain: 2.06 vs. 1.50; p<0.001), limitations in all activities done (Activities domain: 1.18 vs. 0.68; p<0.001), the fear of not having medication available (Emotions domain: 0.99 vs. 0.60; p<0.01), and symptoms from being exposed to dust (Environment domain: 1.31 vs. 0.88; p<0.001), compared to placebo (active control) patients.